MicroPort CardioFlow Medtech Past Earnings Performance

Past criteria checks 0/6

MicroPort CardioFlow Medtech's earnings have been declining at an average annual rate of -15.7%, while the Medical Equipment industry saw earnings declining at 1.1% annually. Revenues have been growing at an average rate of 27.3% per year.

Key information

-15.7%

Earnings growth rate

-8.3%

EPS growth rate

Medical Equipment Industry Growth	4.3%
Revenue growth rate	27.3%
Return on equity	-15.9%
Net Margin	-91.0%
Last Earnings Update	30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How MicroPort CardioFlow Medtech makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:72X Revenue, expenses and earnings (CNY Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Jun 24	383	-349	297	211
31 Mar 24	360	-410	295	224
31 Dec 23	336	-472	293	237
30 Sep 23	319	-491	273	246
30 Jun 23	303	-511	253	254
31 Mar 23	277	-483	243	239
31 Dec 22	251	-454	233	224
30 Sep 22	245	-345	213	203
30 Jun 22	239	-236	193	182
31 Mar 22	220	-209	173	166
31 Dec 21	201	-183	152	151
30 Sep 21	176	-265	131	133
30 Jun 21	151	-346	111	116
31 Mar 21	128	-372	104	106
31 Dec 20	104	-398	97	97
31 Dec 19	22	-145	37	97

Quality Earnings: 72X is currently unprofitable.

Growing Profit Margin: 72X is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 72X is unprofitable, and losses have increased over the past 5 years at a rate of 15.7% per year.

Accelerating Growth: Unable to compare 72X's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 72X is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.2%).

Return on Equity

High ROE: 72X has a negative Return on Equity (-15.92%), as it is currently unprofitable.

MicroPort CardioFlow Medtech Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

First half 2024 earnings released: CN¥0.024 loss per share (vs CN¥0.076 loss in 1H 2023)

MicroPort CardioFlow Medtech Corporation to Report First Half, 2024 Results on Aug 28, 2024

Full year 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.19 loss in FY 2022)

Full year 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.19 loss in FY 2022)

MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2023 Results on Mar 27, 2024

First half 2023 earnings released: CN¥0.076 loss per share (vs CN¥0.052 loss in 1H 2022)

Recent updates

Now 28% undervalued

First half 2024 earnings released: CN¥0.024 loss per share (vs CN¥0.076 loss in 1H 2023)

Now 56% undervalued after recent price drop

MicroPort CardioFlow Medtech Corporation to Report First Half, 2024 Results on Aug 28, 2024

Now 48% undervalued after recent price drop

Full year 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.19 loss in FY 2022)

Forecast to breakeven in 2026

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 26, 2024

Full year 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.19 loss in FY 2022)

MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2023 Results on Mar 27, 2024

Microport Cardioflow Medtech Corporation Receives NMPA Approval for Registration Application of Anchorman LAAC System

MicroPort CardioFlow Medtech Corporation Completes Clinical Implantation Cases in Europe

MicroPort CardioFlow Medtech Corporation Announces First Two Clinical Applications of Third-Generation TAVI Product

First half 2023 earnings released: CN¥0.076 loss per share (vs CN¥0.052 loss in 1H 2022)

MicroPort Cardioflow Medtech Corporation Announces Executive Changes

MicroPort CardioFlow Medtech Corporation to Report First Half, 2023 Results on Aug 29, 2023

New major risk - Share price stability

New minor risk - Share price stability

Less than half of directors are independent

Full year 2022 earnings released: CN¥0.19 loss per share (vs CN¥0.079 loss in FY 2021)

Less than half of directors are independent

Microport Cardioflow Medtech Corporation Announces Registration in Colombia for Alwide Plus Balloon Catheter

First half 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.031 loss in 1H 2021)

MicroPort CardioFlow Medtech Corporation to Report Q2, 2022 Results on Aug 29, 2022

MicroPort CardioFlow Medtech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Microport Cardioflow Medtech Corporation Announces That the Transcatheter Mitral Valve Replacement System Independently Developed by the Group Was Successfully Applied by the Heart Team of Zhongshan Hospital

MicroPort CardioFlow Medtech Announces Appointment of Zhao Liang as Executive Director

Full year 2021 earnings released: CN¥0.079 loss per share (vs CN¥0.23 loss in FY 2020)

MicroPort CardioFlow Medtech Corporation Announces Resignation of Wu Guojia as an Executive Director

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.08 loss per share (vs CN¥0.23 loss in FY 2020)

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 22, 2022

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 22, 2022

Microport Cardioflow Medtech Corporation Successfully Registered Vitaflow Liberty Transcatheter Aortic Valve Implantation System in Argentina

Microport Cardioflow Medtech Corporation Announces Ce Mark Registration Application for Vitaflow Libertytm

No longer forecast to breakeven

Forecast to breakeven in 2023

Independent Non-Executive Director Hualiang Jiang has left the company

MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2020 Results on Mar 30, 2021

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies